Randy F. Sweis
University of Chicago
H-index: 24
North America-United States
Top articles of Randy F. Sweis
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Intratumoral (ITu) delivery of mRNA-2752 encoding human OX40L/IL-23/IL-36γ in combination with durvalumab induces an immunostimulatory effect within the tumor microenvironment … | Cancer Research | Michael Abadier Ryan J Sullivan Jacky Chow Vasudha Sehgal Randy F Sweis | 2024/3/22 |
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024: Featured Updates to the NCCN Guidelines | Journal of the National Comprehensive Cancer Network | Robert J Motzer Eric Jonasch Neeraj Agarwal Ajjai Alva Hilary Bagshaw | 2024/2/1 |
AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation. | Andrea B Apolo Karla V Ballman Guru P Sonpavde Stephanie A Berg William Y Kim | 2024/2/1 | |
Dysregulated FGFR3 signaling alters immune landscape in bladder cancer and presents therapeutic possibilities | Cancer Research | Daniel R Bergman Erica Trujillo Lie Li Alexander T Pearson Randy Sweis | 2024/3/22 |
A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma. | Russell Kent Pachynski Gurkamal S Chatta Rohit K Jain Helen H Moon Randy F Sweis | 2024/2/1 | |
Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model | Frontiers in Immunology | Daniel R Bergman Yixuan Wang Erica Trujillo Anthony A Fernald Lie Li | 2024/3/7 |
Bladder-Preserving Trimodality Therapy With Capecitabine | Clinical Genitourinary Cancer | Connor Lynch Randy F Sweis Parth Modi Piyush K Agarwal Russell Z Szmulewitz | 2024/1/9 |
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy | Cell Reports | Andrea Ziblat Brendan L Horton Emily F Higgs Ken Hatogai Anna Martinez | 2024/5/28 |
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced … | Neurotherapeutics | Scott D Newsome Fan Tian Thomas Shoemaker Kathryn C Fitzgerald Sandra D Cassard | 2023/9/1 |
Melanoma and microbiota: Current understanding and future directions | Bertrand Routy Tanisha Jackson Laura Mählmann Christina K Baumgartner Martin Blaser | 2024/1/8 | |
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer | Clinical Cancer Research | Kunal B Desai Anthony V Serritella Walter M Stadler Peter H O'Donnell Randy F Sweis | 2024/4/26 |
Kidney Cancer, Version 2.2024 Featured Updates to the NCCN Guidelines | JNCCN Journal of the National Comprehensive Cancer Network | Robert J Motzer Eric Jonasch Neeraj Agarwal Ajjai Alva Hilary Bagshaw | 2024/2 |
The development of STING agonists and emerging results as a cancer immunotherapy | Jacobi B Hines Alec J Kacew Randy F Sweis | 2023/3 | |
Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms | Scientific Reports | Yixuan Wang Daniel R Bergman Erica Trujillo Alexander T Pearson Randy F Sweis | 2023/12/18 |
2367P A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial … | Annals of Oncology | R Pachynski G Chatta RK Jain H Moon R Sweis | 2023/10/1 |
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma | European Urology Oncology | Pavlos Msaouel Randy F Sweis Manojkumar Bupathi Elisabeth Heath Oscar B Goodman Jr | 2023/12/16 |
TROPHY-U-01 cohort 6: Sacituzumab govitecan (SG), SG plus zimberelimab (ZIM), SG plus ZIM plus domvanalimab (DOM), or carboplatin (CARBO)+ gemcitabine (GEM) in cisplatin … | Ignacio Duran Andrea Necchi Thomas Powles Yohann Loriot Chethan Ramamurthy | 2023/2/20 | |
Final database lock results of the phase 2 cohort of lenvatinib+ pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell … | The Oncologist | Chung-Han Lee Amishi Yogesh Shah Arpit Rao Matthew H Taylor Alvaro Pinto | 2023/9/1 |
726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study | Susan Henry Stephen DeWall Ulka N Vaishampayan Amna Sher Ahmad A Tarhini | 2023/11/1 | |
Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas | Clinical Cancer Research | Funda Meric-Bernstam Randy F Sweis F Stephen Hodi Wells A Messersmith Robert HI Andtbacka | 2023/6/13 |
